PA
DFTX

Profund Advisors’s Definium Therapeutics DFTX Stock Holding History

Profund Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$268K Sell
14,196
-7,793
-35% -$132K 0.01% 824
2025
Q4 		$294K Buy
21,989
+3,323
+18% +$41.1K 0.01% 887
2025
Q3 		$220K Buy
18,666
+4,959
+36% +$46.2K 0.01% 924
2025
Q2 		$89K Sell
13,707
-3,802
-22% -$25K ﹤0.01% 973
2025
Q1 		$102K Buy
17,509
+5,216
+42% +$37.4K ﹤0.01% 952
2024
Q4 		$85.6K Sell
12,293
-8,550
-41% -$58.8K ﹤0.01% 1081
2024
Q3 		$119K Sell
20,843
-3
-0% -$21 ﹤0.01% 1097
2024
Q2 		$150K Buy
+20,846
New +$182K 0.01% 1019
2022
Q1 		– Sell
-785
Closed -$16K – 1388
2021
Q4 		$16K Buy
785
+106
+16% +$3.38K ﹤0.01% 1372
2021
Q3 		$24K Buy
+679
New +$29.4K ﹤0.01% 1349

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Profund Advisors's DFTX Position: Q1 2026 in Review

Profund Advisors reduced its Definium Therapeutics (DFTX) stake by 35% in Q1 2026, selling an estimated $132K and leaving 14,196 shares worth $268K. The position accounts for 0.01% of the portfolio, ranked #824.

Profund Advisors first reported a position in DFTX in Q3 2021 and has held it in 10 quarters since. The position peaked at $294K in Q4 2025. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Profund Advisors held 14,196 shares of Definium Therapeutics worth $268K as of Q1 2026.
  • Profund Advisors sold 7,793 Definium Therapeutics shares in Q1 2026, an estimated $132K.
  • Definium Therapeutics made up 0.01% of Profund Advisors's portfolio in Q1 2026, its #824 holding.
  • Profund Advisors first reported a position in Definium Therapeutics in Q3 2021 and has held it in 10 quarters since.
  • Profund Advisors's Definium Therapeutics position peaked at $294K in Q4 2025.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.